🇺🇸 FDA
Patent

US 9249415

Complement component C5 iRNA compositions and methods of use thereof

granted A61KA61K31/713A61K39/3955

Quick answer

US patent 9249415 (Complement component C5 iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Feb 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K31/713, A61K39/3955, A61P, A61P1/04